<DOC>
	<DOCNO>NCT01628926</DOCNO>
	<brief_summary>- To demonstrate non-inferiority SPM 962 ropinirole term efficacy order confirm clinical value SPM 962 . - To demonstrate superiority SPM 962 placebo term efficacy . - To investigate tolerability safety SPM 962 36.0 mg/day .</brief_summary>
	<brief_title>A Placebo- Ropinirole-Controlled Study SPM 962 Advanced Parkinson 's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>Subject diagnose Parkinson 's disease accordance `` Diagnostic Criteria establish Research Committee MHLWspecified Intractable Neurodegenerative Diseases ( 1995 ) '' . Subject 30 less 80 year age time informed consent . Hoehn &amp; Yahr stage 24 ( time ) . Total UPDRS Part 3 score 10 screen test ( time ) . Subject stable dose Ldopa change daily dose dose regimen least 28 day prior initial treatment SPM 962 . Subject follow problematic symptom ; 1 ) Wearing phenomenon ( include frozen gait time dystonia time ) 2 ) On phenomenon 3 ) Delayedon and/or Noon phenomenon 4 ) Dyskinesia 5 ) Not well control Ldopa . Subject previously participate clinical trial SPM962 take investigational product ( IP ) . Subject psychiatric symptom , e.g . confusion , hallucination , delusion , excitation , delirium , abnormal behavior screen test baseline . Subject whose SBP decline least 30 mmHg supine stand position base orthostatic hypotension assessment , subject develop orthostatic hypotension baseline . Subject history epilepsy , convulsion . Subject complication history serious cardiac disease arrhythmia ( eg , congestive heart failure class 3 4 NYHA classification , second third degree atrioventricular block , complete leave bundle branch block , sick sinus syndrome , ventricular fibrillation , myocardial infarction within 12 month prior screen test , complication angina pectoris ) . Subjects QTcinterval &gt; 450 msec twice screen . Subject average QTcinterval two ECGs &gt; 450 msec male &gt; 470 msec female baseline . Subject congenital long QT syndrome . Subject whose serum potassium level &lt; 3.5mEq/L screen test . Subject total bilirubin &gt; = 3.0 mg/dL AST ( GOT ) ALT ( GPT ) great 2.5 time upper limit reference range ( &gt; = 100 IU/L ) screen test , suffers complication active phase chronic hepatitis liver cirrhosis . Subject BUN &gt; = 30 mg/dL serum creatinine &gt; = 2.0 mg/dl screen test . Subject history allergic reaction topical agent transdermal patch . Subject history know intolerance/hypersensitivity ropinirole and/or adverse drug reaction prevent subject receiving treatment . Subject pregnant nursing woman plan pregnancy trial . Subject receive therapy prohibit drug specify study protocol . Subject history pallidotomy , thalamotomy , deep brain stimulation fetal tissue transplant . Subject dementia , include DLB PDD ( MMSE score &lt; = 24 screening ) . Subject complication history malignant neoplastic disease , receive treatment disease within 12 month prior screen test . Subject unable give consent . Subject unable properly record information diary . Subject participate another trial IPs receive IPs within 12 week prior commencement study treatment . Investigator judge subject inappropriate study subject reason .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>